-Reuters
CooTek’s Q3 Performance Trails Consensus
CooTek (Cayman) Inc (NYSE:CTK) reported a third-quarter FY21 revenue decline of 52% year-on-year to $51.1 million, missing the consensus of $82.5…
Related Posts
US Foods Reports Mixed Q3 Results, Warns On Supply Chain Headwinds
US Foods Holding Corp (NYSE:USFD) reported third-quarter FY21 sales growth of 35% year-on-year, to $7.89 billion, beating the analyst consensus of…
Renalytix Highlights Study Results For Co.’s KidneyIntelX Published In ‘The American Journal Of Nephrology,’ Showed ‘KidneyIntelX successfully monitors patient response to SGLT2 therapy in 1,325 CANagliflozin CardioVAScular Assessment…’
Renalytix (NASDAQ:RNLX) (LSE: RENX) announced the publication of positive study results for KidneyIntelX™ as a risk monitoring tool to assess impact and response to novel treatments for patients with
Needham Maintains Buy on Cerence, Lowers Price Target to $30
Needham analyst Rajvindra Gill maintains Cerence (NASDAQ:CRNC) with a Buy and lowers the price target from $46 to $30.